Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
Boston scientific has received reports of intermittent oversensing of the minute ventilation (mv) sensor signal with certain boston scientific pacemaker and cardiac resynchronization therapy pacemaker systems (pacemakers). mv sensor signal oversensing may cause pre-syncope or syncope due to periods of pacing inhibition. this mv behavior may occur with any manufacturer’s pacing lead system, but boston scientific has determined it to be more likely for affected boston scientific pacemakers using medtronic or abbott/st. jude (abbott) leads implanted in either the right atrium (ra) or right ventricle (rv).
Action
A software upgrade is being developed for distribution in early 2018. Until this is available to automatically resolve MV sensor signal oversensing, Boston Scientific recommends managing the risk for patients implanted with affected systems as follows:
·Subject to the the guidance supplied to customers, turn the MV sensor to “OFF”
·If transient, abrupt changes or any out-of-range RA/RV pacing impedance measurements are observed, contact Boston Scientific Technical Services to explore all non-invasive programming options prior to surgical intervention
·For patients with the MV sensor enabled, periodically re-assess for pacemaker dependence
Doctors are encouraged to
·Enroll and follow patients using the LATITUDE NXT Remote Patient Management System
·Provide the supplied patient letter to all patients who are implanted with an affected device, and to patients who consent to having the device implanted before the software fix is available
Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
Some patients have reported experiencing an uncomfortable temperature increase at the implantable pulse generator (ipg) implant site during charging, with a small number of patients reporting burns at the implant site. this matter is a follow-up to a hazard alert letter issued by st. jude medical (sjm) in august 2012 (tga reference: rc-2012-rn-00759-3).In the august 2012 letter, st. jude medical informed customers that they would be implementing design improvements to the charger to address the possibility of increased energy dissipation during charging. the new brio le charging system model 6722 and brio le charger accessory model 6720 reduces the potential for uncomfortable temperature increases that may be felt near the ipg while recharging, by automatically turning the energy it delivers on and off. this will require patients to either charge for longer or more frequently to achieve a full charge.
Action
St. Jude Medical recommends the prompt replacement of the charger for patients who have reported excessive heating during charging. For other patients, replacement of the charger is recommended at the next follow-up. Upon replacement, proper charging function of the Brio LE Charger Accessory Model 6720 must be confirmed. The Brio LE Charger System Model 6722 and Brio LE Charger Accessory Model 6720 may not be able to charge implanted IPGs at an implant depth greater than 2.25cm (the Model 6721 was labelled for implant depth up to 2.50 cm). In case of difficulties with the charging function of the Brio LE Charger Accessory Model 6720 due to the depth of the implant, patients should continue to use their current Brio Charger Model 6721, following the precautions provided in the August 2012 letter.
Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
St. jude medical has become aware of a small number of optisure dual coil defibrillation leads that may have had potential insulation damage at the interface of the termination sleeve and svc shock coil in optisure dual coil defibrillation leads. this damage has been determined to have occurred during the manufacturing process.In the event that a subject optisure lead is connected to a device without dynamic tx technology, there is the potential for lead damage to result in loss of defibrillation therapy during attempted shock delivery when programmed to the rv to svc and can high voltage therapy configurationst. jude medical is not aware of any complaints or clinical incidents related to this matter.
Action
Customers are asked to quarantine all unused units prior to return to St Jude Medical. For affected units that have been implanted, St Jude Medical is advising that patients should continue to be managed in accordance with the patient management protocol included in the customer letter. For further information, please see http://www.tga.gov.au/alert/optisure-dual-coil-defibrillation-leads This action has been closed-out on 22/08/2016.
Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
When using the merlin programmer with software version17.2.2 as part of a single vf detection zone configuration for icd/crt-d devices, the sinus redetection value will be inappropriately set to zero milliseconds. as a result, any intrinsic activity following the first shock will be considered a “sinus rate” and the device will diagnose “return to sinus”. therefore, if the arrhythmia was not terminated by the initial high voltage therapy, the ongoing arrhythmia would be considered a new episode causing the next high voltage therapy to also be delivered at the first programmed energy level. for example, if the first shock is programmed to 20 joules and subsequent shocks are programmed to higher energy values, the only hv therapy the patient would receive if the arrhythmia continues and is redetected, would be 20 joules, rather than the increasing hv energy levels as programmed.
Action
Clinicians are advised to review their SJM ICD/CRT-D patient records for patients with affected devices implanted or seen in clinic starting in September 2013 and programmed to a single VF detection zone with the 17.2.2 software. For patients identified during this review St. Jude is recommending to immediately schedule a follow-up visit. For patient devices programmed with 17.2.2 software, a new software version 17.2.3 will correct this issue and is expected to be available by February 2014. Using this software, programming any parameter will reset the return to sinus criteria to normal function. If a patient is seen before the 17.2.3 software is installed, then program the device to a two or three zone configuration, even if one of the zones is strictly a monitor zone. This will resolve the issue when using a programmer with 17.2.2 software. For more details, please see http://www.tga.gov.au/safety/alerts-device-st-jude-medical-icd-crtd-140128.htm . This action has been closed-out on 29/01/2016.
Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
Some patients have reported experiencing an uncomfortable temperature increase at the ipg implant site during charging, with a small number of patients reporting burns at the implant site. this matter is a follow-up to a hazard alert letter issued by st. jude medical (sjm) in august 2012 (tga reference: rc-2012-rn-00759-3). in the august 2012 letter, st. jude medical informed customers that they would be implementing design improvements to the charger to address the possibility of increased energy dissipation during charging. the new eon mini le charging system model 3722 and eon mini le charger model 3720 reduce the potential for uncomfortable temperature increases that may be felt near the ipg while recharging by automatically turning the energy it delivers on and off. this will require patients to charge longer or more frequently to achieve a full charge.
Action
St. Jude Medical recommends the prompt replacement of the charger for patients who have reported excessive heating during charging. For other patients, replacement of the charger is recommended at the next follow up. Upon replacement, proper charging function of the Eon Mini LE Charger Model 3720 must be confirmed. The Eon Mini LE Charging System Model 3722 and Eon Mini LE Charger 3720 may not be able to charge implanted IPGs at an implant depth greater than 2.25cm (the Model 3721 was labelled for implant depth up to 2.50cm). In case of difficulties with the charging function of the Eon Mini LE Charger Model 3720 due to the depth of the implant, patients should continue to use their current Eon Mini Charging System Model 3721 following the precautions provided in the August 2012 letter. This action has been closed-out on 04/04/2017.
Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
A software anomaly has been identified in the merlin@home system that also has the potential to cause software resets for st. jude medical devices. despite the previous software upgrade, a low incidence of back up operation in some implanted st. jude medical devices with radio-frequency (rf) capability has been observed. this may occur as a result of a merlin@home transmitter initiating an implanted device software reset.This issue can only occur when the patient is being actively monitored by a merlin@home rf bedside transmitter.
Action
Surgeons are advised that the majority of ICD and pacemaker devices are non-invasively restored by St. Jude Medical Technical Support over the air. However, in rare cases the device is unable to be restored and replacement may be required. St. Jude Medical has refined the software download procedure to reduce the incidence of failure.
In the event a patient’s device reverts to back-up mode, St Jude Medical Australia recommends bringing the patient back in the clinic to clear the condition and return the device to full functionality.
The Merlin@home transmitter software will be updated to prevent this issue from occurring. The software update will be performed automatically over the telephone, broadband or cellular connection .
Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
Reports of heating at the ipg implantation site during charging of the spinal cord and deep brain stimulators. this is an update to the 'hazard alert' letter dated 05 january 2012 . in the updated letter, st. jude is providing updated occurrence rates, informing hospitals and treating clinicians of four instances of patient burns associated with charging the ipgs and additional patient management recommendations.
Action
St Jude is providing information to implant / treating clinicians on how to manage the patients affected with this issue. For more information, please see http://www.tga.gov.au/safety/alerts-device-ipg-120924.htm
Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
This is an update to the 'hazard alert' letter dated 24 may 2011, pertaining to the eon mini model 3788 and brio model 6788 implantable pulse generators (ipgs) inner battery cracking issues. st. jude medical received reports eon mini and brio ipgs that lost the ability to communicate or recharge due to an inner battery weld issue resulting in loss of pain relief and subsequent explant.
Action
St Jude is providing information to implant / treating clinicians on how to manage the patients affected with this issue. For more information, please refer to the TGA Website http://www.tga.gov.au/safety/alerts-device-ipg-120924.htm
Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
St. jude medical (sjm) is notifying physicians of the risk of premature battery depletion associated with their icds and crt-ds manufactured before may 23, 2015. high voltage icds and crt-ds that utilise lithium-based battery chemistries are subject to lithium cluster formation during high voltage charging. depending on their location, lithium clusters may cause a short circuit that can lead to premature battery depletion. if a short circuit occurs, battery depletion can occur in these devices within a day to a few weeks, which may result in the inability to deliver therapy.Among 398,740 devices sold worldwide, 841 devices returned for analysis due to premature battery depletion have had evidence of lithium material in the form of “clusters” in the battery. forty-six (46) exhibited visible clusters bridging the cathode and anode causing shorting. there have been 2 deaths that have been associated with the loss of defibrillation therapy as a result of premature battery depletion.
Action
SJM is contacting physicians to provide details regarding risk and patient management recommendations. Premature battery depletion can be identified by physicians through remote monitoring or in person visits showing ERI or more advanced battery depletion.Patients may become aware when their device reaches ERI because they may feel a vibratory patient notifier alert.SJM is providing recommendations that include confirming patients can feel and recognise vibratory alerts and reaffirming the availability and usage of remote monitoring to avoid or minimise time without device therapy for bradycardia and tachycardia events. Prophylactic device replacement is not recommended because complications following replacement have been reported to occur at a greater rate than the rate of harm associated with premature battery depletion. SJM is also notifying doctors not to implant any unused affected devices that they may have in their inventory.These devices will be replaced by unaffected stock. This action has been closed-out on 17/05/2017.
Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
The product and product label on the inner pouch do not match the outer product label. the product listed on the inner pouch is correct. use of the affected unit may result in a procedural delay while another occluder of the desired size is obtained.
Action
St. Jude Medical sales representative will contact customers to facilitate removal of the affected product and for providing replacement or issuance of full credit for the removed product.
Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
St. jude medical (sjm) has received complaints that extended charge time may present as a result of internal damage to the capacitors used in the high voltage charging circuitry of the subject devices. as designed, the device will deliver the available energy on the capacitors once the charge time limit of 32 seconds is reached, even if the energy is less than the programmed value. this anomaly may occur during capacitor maintenance or charging for high voltage therapy, and may result in delayed delivery of high voltage therapy and/or delivery of part of a programmed high voltage therapy shock. there have been no reported cases of an ellipse device failing to deliver high voltage therapy to a patient when needed.
Action
St. Jude Medical is providing appropriate patient management recommendations to surgeons for managing patients who are implanted with affected devices. Device replacement is not recommended for an Ellipse device exhibiting normal charge times, and patients should continue to be followed at routine follow-up intervals.
Surgeons are advised not to use any Ellipse devices which may be on their shelves. St. Jude Medical is advising customers that the affected stock will be retrieved and replaced by new Ellipse ICDs with the redesigned high voltage capacitor eliminating the source of capacitor damage at the front alignment hole. Ellipse ICDs with serial numbers beginning with the number “1” and starting at 1132470, as well as Ellipse ICDs with serial numbers beginning with the number “7” and starting with 7126267 incorporate the new capacitors and therefore, no affected. This action has been closed-out on 03/02/2017.
Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
The indication for st. jude medical’s (sjm) occipital nerve stimulation (ons) therapy for the treatment of intractable chronic migraine is being removed from the product instructions for use. the post market clinical follow up data was not appropriate to demonstrate that the benefit of the therapy outweighs the risk at this time. st. jude medical has advised doctors not to use the eon, eon c, eon mini and prodigy scs devices and associated programmers, as well as the octrode and quattrode leads, for the purpose of occipital nerve stimulation. please note that these products are still available for use as an aid in the management of chronic, intractable pain of the trunk and/or limbs.
Action
St. Jude Medical has undertaken this action not following the Uniform Recall Procedure for Therapeutic Goods (URPTG) since they have classified this as a product notification.
The TGA has classified this change as a hazard alert to inform consumers and health professionals of the changed advice relating to St Jude Medical’s occipital nerve stimulation devices and the latest data relating to their use.
Regarding patients who have already been treated for ONS therapy, St Jude Medical is not recommending a change in the way currently implanted patients are followed up.
For more information, please see http://www.tga.gov.au/alert/st-jude-medical-implantable-neurostimulators-and-accessories-various-devices .
Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
St. jude medical has identified that in rare cases devices with radio frequency (rf) communication capability can revert to backup operation settings this issue can occur as a result of a merlin@home transmitter initiating an implanted device software reset. this issue can only occur while the patient is being actively monitored by a merlin@home rf bedside transmitter.
Action
The Merlin@home software will be updated to prevent this issue from occurring. The software update will be performed automatically over the telephone, broadband or cellular connection.
Surgeons are advised that the majority of ICD and pacemaker devices are non-invasively restored by St. Jude Medical Technical Support over the air. However, in rare cases the device is unable to be restored and replacement may be required. St. Jude Medical has refined the software download procedure to reduce the incidence of failure.
Further information will be published on the TGA web site at - http://www.tga.gov.au/current-year-alerts
This action has been closed-out on 14/07/2016.
Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
Some patients have reported experiencing an uncomfortable temperature increase at the ipg implant site during charging, with a small number of patients reporting burns at the implant site. this matter is a follow-up to a hazard alert letter issued by st. jude medical (sjm) in august 2012 (tga reference: rc-2012-rn-00759-3). in the august 2012 letter, st. jude medical informed customers that they would be implementing design improvements to the charger to address the possibility of increased energy dissipation during charging. the new eon charging system model 3726 reduces the potential for uncomfortable temperature increases that may be felt near the spinal cord stimulator while recharging by automatically turning the energy it delivers on and off to reduce the rise in temperature of the spinal cord stimulator and of the charger wand during charging.
Action
St. Jude Medical is recommending to implanting physicians for the prompt replacement of the charger for patients who have reported excessive heating during charging. For other patients, replacement of the charger is recommended at the next follow up. Upon replacement, proper charging function of the Eon Charging System Model 3726 should be confirmed. Until such time that patients have had their chargers replaced, patients should be advised to continue to use their current Eon Mini Charging System following the precautions provided in the August 2012 letter. This action has been closed-out on 09/08/2016.
Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
Extra notes in the data
Reason
St. jude medical's (sjm) data shows that two specific lots of batteries used to power the dm2100a activators may exhibit faster than normal battery depletion. dm2100a activators with batteries from affected lots may exhibit faster than normal low battery status, identified by emitting one low-pitched audible tone and flashing red lights for 9-10 seconds once every hour, or immediately when a button is pressed. additionally, in the event that an activator button is pressed and there is no indication of lights or tones, this is an indication of a depleted battery.
Action
If an activator exhibits any of the above referenced issues, consumers and clinicians are asked to notify their local St. Jude Medical representative and the representative will provide a replacement activator at no cost.
Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
Extra notes in the data
We recommend immediate replacement of the charger for patients who report or have reported excessive heating during charging: - For other patients, replacement of the charger is suggested at the next visit. - After the replacement, the proper operation of the Eon Mini LE Model 3722 Charger must be confirmed. In case of difficulties with the operation of the Eon Mini Model 3722 Charger, due to the depth of the implant, the patient should continue to use the Mini Model 3721 Eon Charger (eg older charger), following the precautions provided in the July letter of 2012. These precautions are as follows: - If the temperature at the implant site becomes uncomfortable during loading: - Stop the recharge until the discomfort disappears and then continue recharging; - Reposition the antenna over the implant site; - Consider a more frequent and shorter recharge; - If the temperature is still uncomfortable, please contact your doctor, SJM representative, or St. Jude Medical Brazil technicians. - Avoid pressing the antenna between the body and a surface that can retain heat, such as a bed or a chair. - The use of topical anesthetics, balsamic medicine, and / or pain relief adhesives at the implant site before or during loading is not recommended as it may reduce the ability to perceive heat or excessive heating near or at the implant site. - Do not carry the device while sleeping. - Do not consume alcohol immediately before or during loading.
Reason
St. jude medical would like to pass on an "important medical device information" regarding the potential overheating or temperature rise at the location where the generator is positioned during the recharge of the implantable pulse generator for eon mini spinal stimulation. some patients may report a temperature rise at the generator implant site during the recharge of the eon mini stimulation system. in brazil, we only had one reported case that was already solved with the change of the loader.
Action
Field Action Code Eon Mini 3788 triggered under the responsibility of the company St. Jude Medical Brasil LTDA. Company will make correction in the field.
Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
Extra notes in the data
In collaboration with the Medical Advisory Committee of St. Jude Medical, the company recommends: Do not implant affected unused devices. Perform routine follow-up of patients according to standard practice. We have included a "Patient Notification Letter" attached to this letter, so you can provide your patients with information to help them with this event. Prophylactic replacement of the device is NOT recommended because the rates of device replacement complications are greater than the risk rate associated with premature battery depletion due to the short lithium deposits induced (see appendix for selected references ). In the case of an ERI indicator on these devices, it is recommended that they be replaced immediately. At this time, there is no factor, method, or test to identify devices with this form of premature battery depletion near the ERI or to accurately predict the remaining battery life once the ERI appears. Physicians should reaffirm the availability of remote monitoring to avoid or minimize time without device therapy for bradycardia and tachycardia events. Enroll patients on the Merlin.net system using the "Direct Alerts" feature to receive immediate alert notification if the ERI is reached. For patients currently enrolled in Merlin.net, remind them of the importance of using remote monitoring. Review the most recent printing of the programmed parameters (see annex with an example). Make sure that in the "Trigger Alerts When" section that the "Device at ERI" parameter is set to "ON" (the nominal is "ON") for both "Show on FastPath" and "Notify Patient" options. "Device at ERI" is set to OFF, it is recommended that the patient is promptly seen to program this parameter to ON Inform patients that an exchange prompt (ERI) triggers a vibrating alert. the patient's device to determine if an ERI alert has been triggered.Perature premature battery depletion can be identified by remote monitoring showing ERI or advanced battery drainage Perform a test on the patient's vibratory notifier to confirm that it can feel, and acknowledge this alert Patients who can not feel the vibrating alert may not know that your device has run out of battery and / or function capacity Advise the patient to enter contact your clinic immediately if they feel the vibrating alert Face-to-face assessment should be performed to determine the reason for the alert, as other non-critical events can also trigger a vibrating alert.
Reason
High voltage devices (icds and trc-ds) that use lithium-based chemical batteries are subject to the formation of lithium deposits during high voltage charging. depending on your location, lithium deposits may cause a short circuit that could lead to premature battery drainage.
Action
Field Action Code CDI's triggered under the responsibility of the company St. Jude Medical Brasil LTDA. Company issued Safety Alert informing about possible premature battery depletion associated with CDI if CDI s St. Jude Medical Brazil Resyncers manufactured before May 2015.
Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
Extra notes in the data
Information for physicians to manage patients who will receive an implant or who already had an implanted HM3 device: • During the implant, by fitting the Outflow Graft to the Pump Cap, a click sound should be heard while the Screw Ring is being tightened. Continue to rotate the screw ring clockwise until it stops completely and stop making click sound for a tight hand tight connection. • If a low-flow alarm persists at any time after implantation, and other potential causes such as hypertension, low preload, right heart failure, and influx occlusion were considered as cause, computed tomography (CT) angiography should be performed to identify possibility of occlusion of the graft of the graft output. • If surgical repair of the exit graft is necessary due to a torsion occlusion, the flexion relief of the exit graft must be reconnected in its original state or repaired to avoid further folds or occlusion of the graft. Physicians who manage patients who exhibit a persistent low-flow alarm should determine home-based patient care recommendations based on a single clinical case. If you wish to notify technical complaints and adverse events use the following channels: Notivisa: Notices of adverse events (AE) and technical complaints (QT) for products subject to Sanitary Surveillance should be made through the NOTIVISA System. To access the System, you must register and select the Health Professional option, if you are a liberal professional or the Institution / Entity option, if you are a professional of an institution / entity. Technovigilance System: Patient or citizen can notify through the Technovigilance System / SISTEC access through the link Additional information: - Date of identification of the problem by the company: 05/04/2018 - Date of notification notice to Anvisa: 04/06/2018 The company that owns the affected product is responsible for contacting its customers in due time. to ensure the effectiveness of the Field Action in progress. It stands out the joint responsibility of the distribution chain and use of health products in maintaining its quality, safety and efficacy, as well as the effectiveness of the Field Action, expressed by RDC 23/2012: "(...) Art 2 ° A holder of registration of health product is the holder of the registration / registration of health product with Anvisa. Single paragraph. The registration holder, as well as other agents involved from the production to the use of the product, or discarding it when applicable, are jointly and severally responsible for maintaining the quality, safety and efficacy of the health products to the final consumer. Art. 12 Distributors of health products shall forward to the registration holder, in a timely manner, the distribution map and other information requested for the notification and execution of field actions. (...) "
Reason
This is a guiding action so doctors can manage patients who will receive an implant or who have already had an implanted hm3 device. the company received reports of flow outflow occlusions by twisting the graft in the hearttmate 3 (hm3) left ventricular assist system. as a result, patients whose devices exhibit these flow occlusions will experience a persistent low-flow alarm. graft twisting in the outflow can result in serious adverse events such as hemodynamic compromise, thrombosis and death.
Action
Field Action Code HM3-04-18 triggered under the responsibility of the company St. Jude Medical Brasil LTDA. Update, correction or complementation of the actions of use.
Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
Extra notes in the data
Since July 2002 around 143,000 CDIS of the EPIC and ATLAS families have been implemented around the world, and around 123000 remain active today. To date, eight devices (among the 143,000) that have lost ventricular sensing have been detected - the risks detrimental to the patient are in the order of 1 in 1 million. The loss of ventricular sensing was attributed to a well-defined but extremely rare timing sequence that occurs in a very short time window (61 microseconds). To date, there have been no reports of injury or death of any patient to St Jude Medical because of the problem cited. According to St. Jude Medical Ltda, a simple software updater of the generator programmer / firmware will solve the problem, being possible, according to information presented by the company, the software update of both implanted equipment and those not yet implemented . For more details, consult the informative letter provided by St. Jude Medical Ltda (http://www.anvisa.gov.br/tecnovigilancia/alertas/anexos_2008/alerta900_carta.pdf). The Anvisa Technovigilance Unit is following up on this case. ## Update (09/03/2009): St. Jude Medical Brasil Ltda informed the UTVIG / Anvisa on 03/12/2008 about the completion of the updating process of the mentioned defibrillators this alert.
Reason
Possibility of loss of ventricular sensing in the implantable cardioverter defibrillators (dcis) of the epic and atlas families.
Action
The company that registers the EPIC and ATLAS cardioverters in Brazil, ST JUDE MEDICAL BRASIL LTDA, started in Brazil an update of the software integrating implantable cardioverter defibrillators (CDIS). Sales teams and clinical field engineers at St. Jude Medical will carry out the software upgrade on the already distributed PCS Merlin and Model 3510 programmers.
Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
Extra notes in the data
ANVISA through the Technovigilance Unit will monitor all relevant actions. If you have any questions, please contact St. Jude Medical Brazil at (11) 5080-5400, and for event notification associated with the use of the equipment, contact ANVISA - Technovigilance Unit by telephoning 61 - 3448 1485 or by tecnovigilancia@anvisa.gov.br.
Reason
The company st. jude medical has detected a low frequency related to a specific supplier's static random access memory chip used in the following st. jude medical cardiac defibrillators: photon dr (model v-230hv) (certain serial numbers); photon micro vr / dr (models v-194 / v-232); atlas vr / dr (models v-199 / v-240). this anomaly may cause a temporary loss of the stimulation function and permanent loss of the defibrillation support. this occurred because the said memory chip could be affected by the cosmic background radiation that reaches the earth. it is common knowledge that cosmic background radiation constantly bombards the earth. while the earth's atmosphere acts as a shield and absorbs much of this cosmic radiation, some amount of high energy particles hits the earth. st. jude medical has determined that when the static access memory (sram) chip is exposed to background levels of atmospheric ionizing cosmic radiation it can cause a high current drain state, causing the problem described above. according to the company, in brazil, 1028 of these devices were implanted.
Action
The company forwarded to the doctors responsible for the implantation of these devices in Brazil a letter alerting them to the problem and with instructions on how to proceed, as follows: • "If it is not already part of your current practice, doctors should routinely monitor the device every 3 months for patients with the affected models listed above. "•" In determining whether additional follow-up will be necessary, consider the low failure rate of the anomaly and the unique and individual needs and medical situations of each patient , including whether the patient is pacemaker dependent or is at high risk of life due to arrhythmias. "•" If a patient's device is detected as in Hardware Reser Mode, you should arrange for replacement of the patient as soon as possible. "•" Continue to provide patients with the usual warnings so they do not miss scheduled appointments and report any changes in symptoms. "
Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
Extra notes in the data
This security alert can be updated at any time. The company undertakes to keep this Agency informed.
Reason
The company st jude informs that, because of having been a victim of accidents, for the health of the population, the products listed in the annex should not be purchased by clients and health professionals.
Action
Those who become aware of the offer of related products should contact the company, ensuring the confidentiality of the informant. St. Jude Medical Brazil Tel. 11 5080 5400 Fax 11 5080 5439 aiwakura@sjm.com lector@sjmbrasil.com br.sjm.com
Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
Extra notes in the data
Reason
St. jude medical (sjm) has identified the potential for the failure of the generator and remote control to properly respond to key presses resulting in unexpected energy delivery or the inability to discontinue energy delivery with the start/ stop button. the buttons on the console and/ or remote may malfunction when the indiff connector or the remote control connector on the console of an impacted generator receives an electrostatic discharge (esd).
Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
Extra notes in the data
Reason
This recall has been initiated due to reports of lost telemetry and pacing output as a result of a battery malfunction associated with st. jude medical (sjm) nanostim leadless cardiac pacemaker (lcp) devices model number s1dlcp. no patient injuries have been reported in association with the loss of bradycardia pacing therapy.
Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
Extra notes in the data
Reason
St. jude medical has identified a risk of premature battery depletion associated with certain st. jude medical icd and crt-d devices manufactured before may 23 2015. there is evidence of lithium material in the form of "clusters" in the battery. some devices exhibited visible clusters bridging the cathode and anode causing shorting. lithium cluster formation is a known phenomenon with this type of battery.
Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
Extra notes in the data
Reason
Since august 2009 smiths medical has received a total of 3 complaints regarding the introducer sheath and the introducer opening being too small for the width of the catheter experienced with port-a-cath and port-a-cath ii implantable venous and arterial access systems and introducer sets. there have been no reports of patient injury or death associated with this issue. investigation of this issue has identified the root cause to be related to the incorrect size introducer being used in several lots of finished goods. an in-depth investigation concluded that the incorrect introducer size was limited to 1 component part (from st. jude medical) which were put into production of 36 smiths medical finished goods lot numbers.